Day: March 4, 2024

SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) — ContextLogic Inc. (d/b/a Wish) (Nasdaq: WISH) (“ContextLogic,” the “Company,” “we” or “our”), one of the largest mobile ecommerce platforms, today reported its financial results for the quarter and fiscal year ended December 31, 2023. Fourth-Quarter Fiscal 2023 Financial HighlightsRevenues: Revenues were $53 million, a decrease of 57% YoYCore Marketplace revenues were $15 million, down 58% YoY Product Boost revenues were $5 million, down 50% YoY Logistics revenues were $33 million, down 57% YoYNet Loss: Net Loss was $68 million, compared to a net loss of $110 million in the fourth quarter of fiscal 2022Net Loss per share was $2.82, compared to a loss of $4.80 per share in the fourth quarter of fiscal 2022Adjusted EBITDA: Adjusted EBITDA(1) was a loss of $54 million, compared...

SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) — Stitch Fix, Inc. (NASDAQ:SFIX), the trusted online personal styling service, today announced its financial results for the second quarter of fiscal 2024, ended January 27, 2024. “The original Stitch Fix vision, to create an easier and more enjoyable way for people to shop for clothing and accessories, remains both relevant and compelling,” said Matt Baer, Chief Executive Officer. “Our transformation efforts are grounded in fully realizing that vision and include both strengthening the foundation of our company and reimagining our client experience. I am encouraged by the progress we continue to make and am confident we have the right strategic priorities in place to set us up to drive sustainable, profitable growth.” During the first quarter of fiscal 2024, we ceased operations of...

– Infrastructure: DBM Global achieved fourth quarter revenue of $353.8 million –– Life Sciences: R2 experienced strong North America unit sales in the fourth quarter –– Spectrum: Broadcasting entered into agreements with PBS stations for new commercial opportunities with ATSC 3.0 – NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) — INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE) announced today its consolidated results for the fourth quarter and full year. Financial Summary(in millions, except per share amounts) Three Months Ended December 31,   Year Ended December 31,  2023   2022   Increase / (Decrease)   2023   2022   Increase / (Decrease)Revenue $ 361.0     $ 409.3     (11.8)%   $ 1,423.0     $ 1,637.3     (13.1) %Net loss attributable to common stockholders $ (9.6 )   $ (7.0 )   (37.1)%   $ (37.6 )   $ (40.8 )   7.8 %Basic...

Quarterly revenue of $81.4 million, representing an increase of 14% year-over-year. Fourth quarter gross margin of 61.9% and an increase in gross profit of 12% year-over-year, which included a $1.9 million inventory write-off in Europe, an impact of 230 basis points to gross margin. Record full year revenue of $322.0 million, representing 12% growth year-over-year. Full year gross margin of 66.4% and gross profit growth of 11% year-over-year. Record Active Buyers of 1.8 million and Orders of 1.8 million in Q4 2023, representing year-over-year growth of 9% and 17%, respectively. Record annual orders of 6.9 million, representing growth of 6% year-over-year.OAKLAND, Calif., March 04, 2024 (GLOBE NEWSWIRE) — ThredUp Inc. (Nasdaq: TDUP, LTSE: TDUP), one of the largest online resale platforms for apparel, shoes, and accessories, today...

Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 millionGuiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2023. “Akoya’s successful 2023 performance reflects the high demand for our leading spatial biology solutions and effective execution of our financial and strategic plan,” said Brian McKelligon, CEO of Akoya Biosciences. “We expanded our installed base to nearly 1,200 instruments, improved platform speeds, and simplified workflows with new offerings of reagents and analysis tools. We anticipate strong topline growth in 2024 and operating cash...

Sold Record Number of Annual EksoHealth Units in 2023 SAN RAFAEL, Calif., March 04, 2024 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2023. Recent Highlights and AccomplishmentsAchieved record revenue of $18.3 million for the 2023 full year, an increase of 42% year-over-year Sold a total of 151 EksoHealth units for the 2023 full year Launched GaitCoach software for EksoNR Announced net proceeds of $3.9 million from a registered direct offering in January 2024“We are excited to have closed 2023 with record revenues driven by strong demand for our EksoHealth devices and expanded offerings across the continuum of care from hospital to...

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023. “We enter 2024 having made significant progress in realizing our strategic transformation. This is the year in which we expect all the key puzzle pieces to come together, setting us up for breakout growth to follow,” said David Fischel, Chairman and CEO. “Our innovation strategy has a strong foundation, and we are pleased with where we stand. Regulatory submissions for our proprietary robotically-navigated ablation catheter have been made in both Europe and the United States, following stellar results from initial clinical use. We have begun formal testing of our smaller...

Quarterly revenue of $163.8 million, up 33% year-over-year Fiscal Fourth Quarter Highlights:Total revenue of $163.8 million GAAP operating margin of (21)%; Non-GAAP operating margin of 8% GAAP net loss per share of $(0.23); Non-GAAP net income per share of $0.15Fiscal Year 2024 Highlights:Total revenue of $579.9 million GAAP operating margin of (32)%; Non-GAAP operating margin of (0.2)% GAAP net loss per share of $(2.75); Non-GAAP net income per share of $0.20SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) —  All-Remote – GitLab Inc. (NASDAQ: GTLB), The DevSecOps Platform, today reported financial results for its fourth quarter and full fiscal year of 2024, ended January 31, 2024. “We delivered a strong fourth quarter and continue to see large enterprise customers standardize on GitLab to realize business value,” said...

–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2023. “Earlier this year, we announced the decision to focus all our resources...